ロード中...
Patient derived xenografts (PDX) predict an effective heparanase-based therapy for lung cancer
Heparanase, the sole heparan sulfate (HS) degrading endoglycosidase, regulates multiple biological activities that enhance tumor growth, metastasis, angiogenesis, and inflammation. Heparanase accomplishes this by degrading HS and thereby facilitating cell invasion and regulating the bioavailability...
保存先:
| 出版年: | Oncotarget |
|---|---|
| 主要な著者: | , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Impact Journals LLC
2018
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5922397/ https://ncbi.nlm.nih.gov/pubmed/29721203 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.25022 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|